Home>>Peptides>>β-Amyloid 29-40 (Amyloid beta-protein(29-40))

β-Amyloid 29-40 (Amyloid beta-protein(29-40))

Catalog No.GC31137

β-Amyloid 29-40 (Amyloid beta-protein(29-40)) Chemical Structure

Size Price Stock Qty
In stock
In stock
In stock

Customer Reviews

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:


β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

β-Amyloid (29-40) is a fragment of Amyloid-β peptide, unsoluble in water, acetonitrile or in a mixture of both in different ratios. Cationic arginine residues is introduced at β-Amyloid (29-40) C-terminus to solubilize β-Amyloid (29-40) and introduce cationicity in this Aβ stretch to enable it to interact with the negatively charged membrane of bacteria. β-Amyloid (29-40) variants shows antimicrobial effect[1]. Single chain variable fragments (scFv's) binds the 17-28 region of Abeta and effectively inhibits in vitro aggregation of Abeta, but binding the carboxyl-terminal region of β-Amyloid (29-40) does not inhibit aggregation[2].

[1]. Harioudh MK, et al. A short non-cytotoxic antimicrobial peptide designed from Aβ29-40 adopts a nanostructure and shows in vivo anti-endotoxin activity. Chem Commun (Camb). 2017 Dec 5;53(97):13079-13082. [2]. Liu R, et al. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry. 2004 Jun 8;43(22):6959-67.

Chemical Properties

Cas No. 184865-04-1 SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
Formula C49H88N12O13S M.Wt 1085.36
Solubility Soluble in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Review for β-Amyloid 29-40 (Amyloid beta-protein(29-40))

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
4 Star
3 Star
2 Star
1 Star
Review for β-Amyloid 29-40 (Amyloid beta-protein(29-40))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.